{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:23:20Z","timestamp":1782915800049,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI094863"],"award-info":[{"award-number":["AI094863"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.072","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T17:31:50Z","timestamp":1557250310000},"page":"3317-3325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome"],"prefix":"10.1016","volume":"37","author":[{"given":"Irina","family":"Tretyakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tibbens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny D.","family":"Jokinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor S.","family":"Lukashevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pushko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.072_b0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7589\/0090-3558-11.2.195","article-title":"Serologic evidence of Venezuelan equine encephalitis in some wild and domestic populations of southern Texas","volume":"11","author":"Smart","year":"1975","journal-title":"J Wildl Dis"},{"key":"10.1016\/j.vaccine.2019.04.072_b0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4269\/ajtmh.1999.60.441","article-title":"Genetic evidence for the origins of Venezuelan equine encephalitis virus subtype IAB outbreaks","volume":"60","author":"Weaver","year":"1999","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.vaccine.2019.04.072_b0015","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1016\/j.vaccine.2007.07.030","article-title":"Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases","volume":"25","author":"Kitchen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.vaccine.2019.04.072_b0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.ento.49.061802.123422","article-title":"Venezuelan equine encephalitis","volume":"49","author":"Weaver","year":"2004","journal-title":"Annu Rev Entomol"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2019.04.072_b0030","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2009.07.095","article-title":"Vaccines for Venezuelan equine encephalitis","volume":"27","author":"Paessler","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0035","doi-asserted-by":"crossref","first-page":"16038","DOI":"10.1073\/pnas.1111650108","article-title":"Arbovirus high fidelity variant loses fitness in mosquitoes and mice","volume":"108","author":"Coffey","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.04.072_b0040","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1006\/viro.1993.1421","article-title":"Diversity within natural populations of eastern equine encephalomyelitis virus","volume":"195","author":"Weaver","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.04.072_b0045","first-page":"209","article-title":"Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells","volume":"73","author":"Berge","year":"1961","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.04.072_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/epirev\/mxj003","article-title":"Immunization to protect the US Armed Forces: heritage, current practice, and prospects","volume":"28","author":"Grabenstein","year":"2006","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.vaccine.2019.04.072_b0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7205\/MILMED.170.4S.92","article-title":"History of U.S. military contributions to the study of viral encephalitis","volume":"170","author":"Hoke","year":"2005","journal-title":"Mil Med"},{"key":"10.1016\/j.vaccine.2019.04.072_b0060","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0264-410X(98)00315-6","article-title":"TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus","volume":"17","author":"Phillpotts","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0070","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.vaccine.2011.01.055","article-title":"Stability of RNA virus attenuation approaches","volume":"29","author":"Kenney","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0075","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.vaccine.2012.12.050","article-title":"Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine","volume":"31","author":"Tretyakova","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0080","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4049\/jimmunol.87.5.509","article-title":"Tigertt WD. Studies on the virus of Venezuelan equine encephalomyelitis. II. Modification by specific immune serum of response of central nervous system of mice","volume":"87","author":"Berge","year":"1961","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0085","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses","volume":"75","author":"Pushko","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0090","unstructured":"Pushko P, Parker, M.D., Smith, J.F., Crise, B.J. Live attenuated Venezuelan Equine encephalitis vaccine. U.S. Patent 6296854. In: USPTO, editor; 2001."},{"key":"10.1016\/j.vaccine.2019.04.072_b0095","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1128\/JVI.77.10.5740-5748.2003","article-title":"Vesicular stomatitis viruses with rearranged genomes have altered invasiveness and neuropathogenesis in mice","volume":"77","author":"Flanagan","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0100","doi-asserted-by":"crossref","first-page":"10857","DOI":"10.1128\/JVI.01024-16","article-title":"Attenuated infectious hematopoietic necrosis virus with rearranged gene order as potential vaccine","volume":"90","author":"Rouxel","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0105","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1128\/jvi.67.3.1269-1277.1993","article-title":"Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein","volume":"67","author":"Kinney","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0110","doi-asserted-by":"crossref","first-page":"11344","DOI":"10.1073\/pnas.0402905101","article-title":"Venezuelan equine encephalitis emergence: enhanced vector infection from a single amino acid substitution in the envelope glycoprotein","volume":"101","author":"Brault","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.04.072_b0115","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4269\/ajtmh.1987.36.194","article-title":"Vector competence of Culex (Melanoconion) taeniopus for allopatric and epizootic Venezuelan equine encephalomyelitis viruses","volume":"36","author":"Scherer","year":"1987","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.04.072_b0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7774\/cevr.2014.3.1.58","article-title":"Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses","volume":"3","author":"Go","year":"2014","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2019.04.072_b0125","first-page":"1015","article-title":"Update on immunizations in adults","volume":"84","author":"Vaughn","year":"2011","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.vaccine.2019.04.072_b0130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/030098589803500508","article-title":"Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H\/HeN and BALB\/c mice","volume":"35","author":"Steele","year":"1998","journal-title":"Vet Pathol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0135","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1016\/S0264-410X(03)00328-1","article-title":"Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models","volume":"21","author":"Pratt","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0140","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.vaccine.2006.10.030","article-title":"Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses","volume":"25","author":"Fine","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0145","doi-asserted-by":"crossref","first-page":"9278","DOI":"10.1128\/JVI.77.17.9278-9286.2003","article-title":"Recombinant sindbis\/Venezuelan equine encephalitis virus is highly attenuated and immunogenic","volume":"77","author":"Paessler","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0150","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1128\/JVI.80.6.2784-2796.2006","article-title":"Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN\/VEE viruses","volume":"80","author":"Paessler","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01766-16","article-title":"Ablation of programmed -1 ribosomal frameshifting in venezuelan equine encephalitis virus results in attenuated neuropathogenicity","volume":"91","author":"Kendra","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003797","article-title":"IRES-containing VEEV vaccine protects cynomolgus macaques from IE venezuelan equine encephalitis virus aerosol challenge","volume":"9","author":"Rossi","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.072_b0165","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01274-17","article-title":"Novel insect-specific Eilat virus-based chimeric vaccine candidates provide durable, mono- and multivalent, single-dose protection against lethal alphavirus challenge","volume":"92","author":"Erasmus","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0170","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0264-410X(98)00335-1","article-title":"Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors","volume":"17","author":"Hodgson","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0175","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jviromet.2009.11.006","article-title":"A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV)","volume":"163","author":"Fine","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.04.072_b0180","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.vaccine.2010.02.056","article-title":"Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus","volume":"28","author":"Martin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0185","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.vaccine.2009.10.126","article-title":"Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB","volume":"28","author":"Martin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0190","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.vaccine.2010.11.033","article-title":"Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development","volume":"29","author":"Sharma","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.072_b0195","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/CVI.00030-11","article-title":"A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates","volume":"18","author":"Dupuy","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.04.072_b0200","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.1016\/j.vaccine.2010.09.005","article-title":"Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates","volume":"28","author":"Dupuy","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.072_b0205","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4161\/hv.20300","article-title":"Host responses to live-attenuated Venezuelan equine encephalitis virus (TC-83): comparison of na\u00efve, vaccine responder and nonresponder to TC-83 challenge in human peripheral blood mononuclear cells","volume":"8","author":"Erwin-Cohen","year":"2012","journal-title":"Human Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2019.04.072_b0210","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/viro.1995.1458","article-title":"Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1","volume":"212","author":"Davis","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.04.072_b0215","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0042-6822(89)90526-6","article-title":"In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant","volume":"171","author":"Davis","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.04.072_b0220","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/1743-422X-8-356","article-title":"Infectious alphavirus production from a simple plasmid transfection+","volume":"8","author":"Steel","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2019.04.072_b0225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jviromet.2006.11.024","article-title":"An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials","volume":"141","author":"Surman","year":"2007","journal-title":"J Virol Methods"},{"issue":"4523","key":"10.1016\/j.vaccine.2019.04.072_b0230","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.6272391","article-title":"Cloned poliovirus complementary DNA is infectious in mammalian cells","volume":"214","author":"Racaniello","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.04.072_b0235","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1073\/pnas.1834270100","article-title":"DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus","volume":"100","author":"Hall","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.04.072_b0240","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/infdis\/jiu114","article-title":"DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice","volume":"209","author":"Tretyakova","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.072_b0245","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.virol.2014.07.050","article-title":"Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice","volume":"468\u2013470","author":"Tretyakova","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.04.072_b0250","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virol.2017.09.005","article-title":"Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB\/c mice","volume":"512","author":"Nickols","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.04.072_b0255","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/14760584.2016.1175943","article-title":"DNA-launched live-attenuated vaccines for biodefense applications","volume":"15","author":"Pushko","year":"2016","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:31:48Z","timestamp":1759401108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19305602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":51,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19305602"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}